The Hip Fracture Surgical Approach Trial
Launched by DIAKONHJEMMET HOSPITAL · Nov 21, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Hip Fracture Surgical Approach Trial (HIFSAT) is a study designed to compare two different surgical methods for treating patients with a specific type of hip fracture, known as a femoral neck fracture. The trial will look at the traditional surgery called the direct lateral approach and a new technique called the muscle-sparing approach (SPAIRE). The goal is to see which method may offer better outcomes for recovery.
To participate in this trial, you need to be over 50 years old and have a femoral neck fracture that requires a type of surgery called hemiarthroplasty, which involves replacing the damaged part of your hip joint. Unfortunately, if you have had a hip implant in the same hip before, or if you are not expected to survive for more than a week, you won't be eligible to join. If you choose to participate, you can expect to be part of a study that aims to improve hip fracture surgery and recovery for future patients. The trial is currently recruiting participants of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Femoral neck fracture
- • Clinical indication for hemiarthroplasty
- • Age over 50 years
- Exclusion Criteria:
- • Previous hip implants in the same hip
- • Patients assessed to be in a terminal state with an expected survival of less than 1 week
- • Other factors that makes follow-up impossible
About Diakonhjemmet Hospital
Diakonhjemmet Hospital is a leading healthcare institution in Norway, dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the hospital fosters a research environment that prioritizes patient safety and ethical standards. Committed to translating scientific findings into clinical practice, Diakonhjemmet Hospital engages in a diverse range of studies across various medical fields, aiming to enhance treatment outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Trial Officials
Siri Lillegraven, PhD
Study Chair
Diakonhjemmet Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported